Exhibit 5.1
| | |
25 January 2021 | | Our Ref: JWYL/THTW/G3359-H19501 |
Genetron Holdings Limited
Walkers Corporate Limited
Cayman Corporate Centre
27 Hospital Road
George Town
Grand Cayman KY1-9008
Cayman Islands
Dear Sirs
Genetron Holdings Limited
We have acted as Cayman Islands legal advisers to Genetron Holdings Limited (the “Company”) in connection with the filing by the Company of a Registration Statement on Form S-8 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), in relation to the registration of 23,293,767 ordinary shares of a nominal or par value of US$0.00002 each of the Company (“Ordinary Shares”) issuable pursuant to the Company’s 2019 Genetron Health Share Incentive Plan (the “2019 Plan”), 2,685,000 Ordinary Shares issuable pursuant to the Company’s 2019 Genetron Health Share Incentive Scheme (the “2019 Scheme”), and 28,812,833 Ordinary Shares issuable pursuant to the 2019 Plan and the 2019 Scheme (together, the “Plans”, and all such Ordinary Shares issuable pursuant to the Plans, the “Shares”). The Registration Statement (including the Prospectus) provides for the registration by the Company of American Depositary Shares (the “ADSs”) representing the Shares. We are furnishing this opinion as exhibit 5.1 to the Registration Statement.
For the purposes of giving this opinion, we have examined and relied upon the originals, copies or translations of the documents listed in Schedule 1 (the “Documents”).
In giving this opinion we have relied upon the assumptions set out in Schedule 2, which we have not independently verified.
We are Cayman Islands Attorneys at Law and express no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date of this opinion. We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction. Except as explicitly stated herein, we express no opinion in relation to any representation or warranty contained in any of the documents cited in this opinion nor upon matters of fact or the commercial terms of the transactions the subject of this opinion.